Page 5 - Immunology_11_2021

SPARK THE 1.5 mg/0.5 mL

MOTIVATION FOR CHANGE

IN YOUR TYPE 2 DIABETES PATIENTS

Powerful dose from the start without the need to titrate¹

Powerful HbA1c Proven CV benefit Simple once-weekly Better adherence
reduction 1,* in patients with or dosing in a shown in real-world
without established ready-to-use pen with studies vs. other
CVD 2,3,† hidden needle 1,4 GLP-1 RAs 5,6‡

*Trulicity 1.5mg demonstrated statistically superior HbA1C in patients with type 2 diabetes in 8 phase III clinical trials vs metformin, sitagliptin, exenatide BID, insulin glargine, and/or placebo. Trulicity 1.5mg demonstrated
noninferior HbA1c reduction vs liraglutide 1.8mg, as well as noninferiority vs insulin glargine in patients with type 2 diabetes and CKD 1 PP-DG-ZA-0359
† Trulicity 1.5mg significantly reduced the risk of MACE-3 (composite of non-fatal MI, non-fatal stroke, or CV death) vs. placebo by 12% on top of standard of care. CV benefit was consistent across subgroups of patients with
and without estabalished CVD 2,3
‡ In real-world studies, ~40% more patients with T2DM were adherent to once-weekly Trulicity relative to once-weekly semaglutide, Moreover, persistence with Trulicity was the highest among GLP1 RAs including twice daily
exenatide, once-weekly exenatide, liraglutide and lixisenatide
References: 1. Trulicity (dulaglutide once weekly) Trulicity Professional Information, Eli Lilly and Company, Johannesburg, South Africa - 2020. 2. Gerstein HC, et al. Lancet. 2019 ;394:121-130 3. Gerstein HC, et al. Diabetes
Obes Metab. 2018;20:42-49 4. Trulicity 1.5mg instructions for use 5. Mody R, et al. Diabetes Obes Metab.2021;23:106-115. 6. Divino V, et al. Diabetes Ther. 2019;10:1067-1088

Trulicity ® . Reg No. 51/21.13/0344 Dulaglutide 1,5 mg/ 0,5ml solution for injection. For more product information, please email us at: za_medinfo@lilly.com
S4
For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07 1st Floor, Golden Oak
House, Ballyoaks Office Park, 35 Ballyclare Drive, Bryanston, JohannesburgTel: +27 (11) 510 9300
© 2020 Eli Lilly and Company. All Rights Reserved.